Biomea Fusion Q3 EPS $(0.78) Down From $(0.43) YoY

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.78) per share. This is a 81.4 percent decrease over losses of $(0.43) per share from the same period last year.

byBenzinga Newsdesk

November 7, 2022

1 minute read

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.78) per share. This is a 81.4 percent decrease over losses of $(0.43) per share from the same period last year.

RBC Capital Initiates Coverage On Graphite Bio with Sector Perform Rating, Announces Price Target of $11

By Benzinga Newsdesk

February 18, 5:51 AM

RBC Capital analyst Luca Issi initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Sector Perform rating and announces Price Target of $11.

GRPH

Morgan Stanley Initiates Coverage On Canadian Natural Res with Equal-Weight Rating, Announces Price Target of C$53

By Benzinga Newsdesk

October 7, 9:48 AM

Morgan Stanley analyst Devin McDermott initiates coverage on Canadian Natural Res (TSX:CNQ) with a Equal-Weight rating and announces Price Target of C$53.

TSX:CNQ

Cardiff Oncology To Present Posters At American Association For Cancer Research Apr. 11-12, 2022

By Benzinga Newsdesk

March 8, 5:48 PM

Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the publication of two abstracts that have

CRDF